BioSpace News Archive

Bellerophon Therapeutics, Inc. today provided a clinical program update and reported financial results for the second quarter ended June 30, 2022.

Beta Bionics, Inc. — a clinical-stage medical technology company committed to the design, development, and commercialization of the iLet® Bionic Pancreas System — announced the appointment of Sean Saint to the role of Chief Executive Officer.

Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the “Company” or “we”) today announced its operating and financial results for the second quarter ended June 30, 2022.

Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators to treat rare pediatric and adult liver diseases, today provided a business update and reported financial results for the quarter ended June 30, 2022.

Maravai LifeSciences, Inc., a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences during the month of September.

VBL Therapeutics, a biotechnology company developing targeted medicines for immune-inflammatory diseases, announced financial results for the second quarter ended June 30, 2022 and provided a corporate update.

Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, today reported second quarter 2022 financial results and provided a corporate update.

Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported financial results for the quarter ended June 30, 2022.

Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced second-quarter 2022 financial results and provided a corporate update.

OrthoPediatrics Corp. announced the closing of its underwritten public offering of 1,091,250 shares of its common stock at a public offering price of $55.00 per share and in lieu of common stock, pre-funded warrants to purchase up to 1,525,000 shares of common stock at an offering price of $54.99975 per pre-funded warrant and with an exercise price of $0.00025 per share.